# Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients

> **NCT04713176** · PHASE3 · TERMINATED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 240 (actual)

## Conditions studied

- Severe COVID-19

## Interventions

- **DRUG:** DWJ1248 with Remdesivir
- **DRUG:** Placebo with Remdesivir

## Key facts

- **NCT ID:** NCT04713176
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-02
- **Primary completion:** 2022-05-02
- **Final completion:** 2022-12-09
- **Target enrollment:** 240 (ACTUAL)
- **Why stopped:** Termination of study due to sponsor's internal decision
- **Last updated:** 2023-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04713176

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04713176, "Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04713176. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*